July 23
- BPC-157: ulcerative colitis
- KPV: wound healing and inflammatory conditions
- TB-500: wound healing
- MOTs-C: obesity and osteoporosis
Primary-source explainer · last source check July 12, 2026
Discussion is not approval.
FDA’s advisory committee will discuss seven peptide families for possible inclusion on the section 503A Bulks List. The committee advises FDA; its recommendations are nonbinding.
Agenda
What FDA says it will discuss.
These are uses FDA reviewed for this meeting, not approved indications. FDA's agenda identifies free base and acetate forms for each listed peptide family.
July 24
- Emideltide/DSIP: opioid withdrawal, chronic insomnia, and narcolepsy
- Semax: cerebral ischemia, migraine, and trigeminal neuralgia
- Epitalon: insomnia
Boundary
What a meeting cannot prove.
Not drug approval
A discussion or vote does not make a substance an FDA-approved drug.
Not product verification
It does not authenticate a seller, batch, vial, COA, purity claim, or sterility claim.
Not a blanket compounding authorization
Section 503A contains multiple conditions. A substance question is only one part of a larger legal framework.
Category 2
“Nominated but withdrawn” needs careful wording.
FDA’s current significant-safety-risk page places these peptides under “Bulk drug substances nominated but withdrawn,” stating that they were previously in Category 2 and were withdrawn by nominators. That is not an approval or a finding that earlier risk concerns disappeared.
FDA’s page still publishes substance-specific concerns involving limited human data, immunogenicity, peptide-related impurities, aggregation, or API characterization, depending on the substance.
Docket note
Use FDA-2025-N-6895.
FDA’s event page contains a conflicting number in one instructions paragraph. The official Federal Register notice repeatedly identifies FDA-2025-N-6895. Recheck the live page before filing or publishing.
Primary sources